ReviewInternational journal of molecular sciences2022
Emerging Role of NLRP3 Inflammasome and Pyroptosis in Liver Transplantation.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Gut microbiota and postoperative complications in colorectal surgery and its potential association with intestinal permeability and NLRP6 inflammasome.Frontiers in immunology · 2025Pooled it
- Pathophysiological mechanisms of cell death affecting graft survival in liver transplantation.World journal of transplantation · 2026Review
- Recipient-derived macrophages mediate acute cardiac allograft rejection via GSDMD-induced pyroptosis mechanism.Clinical and translational medicine · 2026Article
- Galectin-3 Promotes Graft Injury via NLRP3 Pyroptosis in Steatotic Liver Transplantation: A Therapeutic Target for Donor Optimization.Journal of clinical and translational hepatology · 2026Article
- Spirulina Preconditioning Attenuates Ischemia-Reperfusion Injury in a Steatotic Rat Liver Model.Antioxidants (Basel, Switzerland) · 2026Article
- Regulated cell death in organ transplantation: recent developments and mechanistic overview.Journal of molecular cell biology · 2026Review
- Bimodal regulation and precision therapy of neutrophil extracellular traps in liver ischemia-reperfusion injury: recent advances.Frontiers in immunology · 2026Review
- Non-Invasive Redox Biomarkers Detected in Organ Preservation Outflow Solution Enable Early Prediction of Human Liver Allograft Dysfunction.Antioxidants (Basel, Switzerland) · 2025Article
- Exploring cell death mechanisms in liver transplantation: implications for graft survival.Frontiers in immunology · 2025Review
- Immune responses in rodent whole eye transplantation: elucidation and preliminary investigations into rejection diagnosis and monitoring.Frontiers in immunology · 2025Article
- Circadian immune system in solid organ transplantation: a review article.Frontiers in immunology · 2025Review
- Regulated cell death and DAMPs as biomarkers and therapeutic targets in normothermic perfusion of transplant organs. Part 1: their emergence from injuries to the donor organ.Frontiers in transplantation · 2025Review
- Regulated cell death and DAMPs as biomarkers and therapeutic targets in normothermic perfusion of transplant organs. Part 2: implementation strategies.Frontiers in transplantation · 2025Review
- The impact of ischemia-free liver transplantation on improving the prognosis of recipients using functionally marginal liver grafts: Editorial on "Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts".Clinical and molecular hepatology · 2024Article
- Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts.Clinical and molecular hepatology · 2024Article
- Detection of inflammasome activation in liver tissue during the donation process as potential biomarker for liver transplantation.Cell death discovery · 2024Article
- NLRP3 Inflammasome in Acute and Chronic Liver Diseases.International journal of molecular sciences · 2024Review
- Attenuating Atherosclerosis through Inhibition of the NF-Cardiovascular therapeutics · 2024Article
- Chronic Liver Disease: Latest Research in Pathogenesis, Detection and Treatment.International journal of molecular sciences · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The nucleotide-binding domain leucine-rich repeat-receptor, pyrin domain-containing-3 (NLRP3) inflammasome contributes to the inflammatory response by activating caspase-1, which in turn participates in the maturation of interleukin (IL)-1β and IL-18, which are mainly secreted via pyroptosis. Pyroptosis is a lytic type of cell death that is controlled by caspase-1 processing gasdermin D. The amino-terminal fragment of gasdermin D inserts into the plasma membrane, creating stable pores and enabling the release of several proinflammatory factors. The activation of NLRP3 inflammasome and pyroptosis has been involved in the progression of liver fibrosis and its end-stage cirrhosis, which is among the main etiologies for liver transplantation (LT). Moreover, the NLRP3 inflammasome is involved in ischemia-reperfusion injury and early inflammation and rejection after LT. In this review, we summarize the recent literature addressing the role of the NLRP3 inflammasome and pyroptosis in all stages involved in LT and argue the potential targeting of this pathway as a future therapeutic strategy to improve LT outcomes. Likewise, we also discuss the impact of graft quality influenced by donation after circulatory death and the expected role of machine perfusion technology to modify the injury response related to inflammasome activation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.